AZD 9684Alternative Names: AZD9684
Latest Information Update: 25 Mar 2017
At a glance
- Originator AstraZeneca
- Class Antithrombotics
- Mechanism of Action Carboxypeptidase U inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 01 May 2007 Discontinued - Phase-II for Thrombosis in United Kingdom (IV)
- 20 Jun 2005 This compound is still in active development
- 12 Oct 2004 Phase-II clinical trials in Thrombosis (unspecified route)